In the history of weird musical instrument interfaces, isomorphic keyboards are a favorite. These keyboards look like a grid of buttons, but when you play them, the relative shapes of chords are ...

In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding within Google parent company Alphabet, raising $600 million to advance its ...

Isomorphic Labs was spun out of Google DeepMind, after the tech giant achieved one of the biggest biological breakthroughs in the last 50 years. Demis Hassabis is at the helm of both Isomorphic and ...

Last year, DeepMind’s AlphaFold2 AI system made a “significant contribution to humanity’s understanding of biology.” Alphabet has now taken that advancement and created a new company called Isomorphic ...

Dr. Chris Hillman, Global AI Lead at Teradata, joins eSpeaks to explore why open data ecosystems are becoming essential for enterprise AI success. In this episode, he breaks down how openness — in ...

Isomorphic Labs, the London-based, drug discovery–focused spinout of Google AI R&D division DeepMind, today announced that it’s entered into strategic partnerships with two pharmaceutical giants, Eli ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...

The field of drug discovery has been supercharged by the capabilities of AI, which several companies have applied in various ways to turn an enormous practical problem into a tractable information ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...